Collectively, our data indicate that PLA2G4A expression may hold therapeutic and prognostic potential for the stratification of AML patients and might play a special role in subtypes with MLL-fusions and/or elevated HOXA9 and MEIS1 levels. Here, KMT2A is linked to acute myeloid leukemia.